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Summary 
The neurofibromatosis type i (NF1) gene encodes a tumor suppressor protein, neurofibromin, which is ex- 
pressed at high levels in Schwann cells and other adult tissues. Loss of NF1 expression has been reported in 
Schwann cell tumors (neurofibrosarcomas) from patients with NF1 and its loss is associated with increased 
proliferation of these cells. In this report, we describe downregulation of NF1 expression in a single spinal 
schwannoma from an individual without clinical features of neurofibromatosis type 1 or 2. Barely detectable 
expression of NF1 RNA was found in this tumor by in situ hybridization using an NFl-specific riboprobe as 
well as by Northern blot and reverse-transcribed (RT)-PCR analysis, in Schwann cells cultured from this 
schwannoma, abundant expression of NF1 RNA could be detected by Northern blot and RT-PCR analysis. 
These results suggest that, in some tumors, expression of NF1 may be downregulated by factors produced 
within the tumor and may represent a novel mechanism for inactivating these growth suppressing genes and 
allowing for increased cell proliferation in tumors. 
Introduction 
Tumor suppressor genes (TSGs) are operationally 
defined by their altered expression in cancer cells 
[1]. Their absent or aberrant expression in tumors is 
hypothesized to result in loss of normal cell growth 
control, leading to the increased cell proliferation 
associated with progression to malignancy. The 
neurofibromatosis type i (NF1) gene is such a TSG 
whose expression is reduced in a wide variety of hu- 
man cancers [2]. NF1 is an autosomal dominant dis- 
order in which affected individuals manifest an in- 
creased incidence of tumor development [3]. These 
include benign tumors, such as optic pathway glio- 
mas and neurofibromas, as well as malignant tu- 
mors like neurofibrosarcomas, pheochromocyto- 
mas, rhabdomyosarcomas and leukemias [4]. 
NF1 encodes a large 250 kDa protein, neurofi- 
bromin, expressed in a wide variety of cell types in- 
cluding Schwann cells, oligodendrocytes, neurons 
and leukocytes [5, 6]. Since the hallmark of the dis- 
order is the neurofibroma, a tumor composed pre- 
dominantly of Schwann cells, initial studies have fo- 
cused on the role of neurofibromin in Schwann cell 
growth control and demonstrated that neurofibro- 
min expression increases during in vitro rat 
Schwann cell differentiation [7]. This result sug- 
gests that neurofibromin might play an important 
role in normal Schwann cell growth and differentia- 
tion such that its reduced expression in neurofibro- 
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mas or schwannomas might be associated with in- 
creased Schwann cell proliferation. 
Examination of neurofibrosarcoma cell lines 
(malignant Schwann cell tumors derived from neu- 
rofibromas) from patients with NF1 have demon- 
strated altered NF1 expression [8, 9]. Lack of neuro- 
fibromin expression correlated with increased lev- 
els of activated p21-ras, consistent with the function 
of neurofibromin as a GTPase-activating protein 
for p21-ras. As part of an ongoing study to examine 
the expression of neurofibromin in human 
Schwann cell tumors, we found one patient without 
clinical features of NF1 or NF2 (bilateral vestibular 
neurofibromatosis) who presented with a spinal 
schwannoma lacking expression of NF1. In this re- 
port, we demonstrate that the Schwann cells cultur- 
ed from this tumor, unlike the tumor itself, have 
abundant NF1 expression. These results suggest 
that NF1 expression might be downregulated in se- 
lected tumors through mechanisms other than mu- 
tation and offer the possibility that neurofibromin 
expression may be regulatable in selected tumors. 
Materials and methods  
Tumors 
Fresh surgical tissue from the spinal schwannoma 
was obtained in the operating room according to 
the guidelines established by the Washington Uni- 
versity Institutional Review Board (IRB protocol 
# 93-0725) and divided into three portions. One 
portion was wrapped in aluminum foil and immedi- 
ately snap-frozen in liquid nitrogen and stored at 
- 70 ~ C. Another portion was immersed in fresh 4 % 
paraformaldehyde in 0.1 M phosphate buffer, pH 
7.4 for 24 hours at 4 ~ C prior to processing for in situ 
hybridization and immunohistochemistry. The 
third portion was placed in Dulbecco's Modified 
Essential Medium (DMEM) containing 10% fetal 
bovine serum (Gibco-BRL) and 1% pencillin/strep- 
tomycin for culturing of Schwann cells and fibro- 
blasts. 
Culturing of tumor Schwann cells 
Cells were enzymatically dissociated from tumor 
tissue or adult human peripheral nerve and at- 
tached to glass coverslips or 10 cm plastic dishes 
coated with poly-L-lysine as previously described 
[10]. Fibroblasts were purified by serial subculture 
on uncoated plastic in basal feeding medium con- 
sisting of Dulbecco's modified Eagle's medium con- 
taining 10% heat-inactivated fetal bovine serum, 
200 U/ml penicillin and 0.2 mg/ml streptomycin. 
After four successive passages, the cultures con- 
tained > 98% fibroblasts as determined by indirect 
immunofluorescent staining for a fibroblast surface 
protein [11]. Schwann cells were propagated in basal 
feeding medium supplemented with conditioned 
medium from a transfected CHO cell line secreting 
recombinant human glial growth factor [12] and 
0.5 mM forskolin and 0.5 mM isobutylmethylxan- 
thine to suppress fibroblast growth (JLR, manu- 
script in preparation). These cultures contained 
predominantly Schwann cells which were identified 
by indirect immunofluorescent staining for S-100 
protein expression [10]. 
Riboprobe production 
A cDNA containing nucleotides 8237 to 8457 of 
NF1 [13] was cloned into pBlueScript II. KS (-). To 
synthesize antisense and sense riboprobes, this 
plasmid was linearized with the appropriate restric- 
tion endonucleases (Sal 1 for sense and Xba 1 for 
antisense) and transcribed in vitro in the presence 
of 90 gCi [3sS]UTP (Amersham) using either T7 
(sense) or T3 (antisense) RNA polymerases. 
In situ hybridization 
The in situ hybridization procedures employed in 
our laboratory follow the method described else- 
where [14]. Briefly, individual sections were hybrid- 
ized overnight at 55-60 ~ C with either antisense or 
sense riboprobes (1 x 106 cpm/slide) diluted in a 60 
microliters of hybridization mixture containing 
50% deionized formamide, 10% dextran sulfate, 1 x 
Denhardt's, 4 x SSC, 10 mM dithiothreitol, I mg/ml 
yeast tRNA, and 1 mg/ml denatured salmon sperm 
DNA. The following day, the sections were rinsed 
twice in 4 x SSC for 30 min at 37 ~ C, treated with 
RNase A (40 gg/ml) for 30 min at 45 ~ C and then 
rinsed at 37 ~ C in 2 x SSC (2 x 20 rain); 0.5 x SSC 
(2 x 20 min), and 0.1 x SSC (30 min). The sections 
were then briefly dipped in distilled water, followed 
by 95% ethanol, and air dried. Sections were ex- 
posed to BioMax film (Kodak) for 3 days to gener- 
ate film autoradiograms, and then dipped in Kodak 
NTB-2 liquid emulsion and stored in dessicated 
light-tight boxes at 4 ~ C for 10-15 days. Slides were 
developed in Kodak D19 and fixed in Kodak Fixer, 
rinsed in distilled water, counterstained with hema- 
toxylin and eosin, dehydrated, and coverslipped 
with 50% DPX. 
Control experiments were performed to assess 
the specificity of the riboprobes. Sections were in- 
cubated with individual sense strand 35S-labeled ri- 
boprobes or were pretreated with RNase A 
(Boehringer Mannheim; 20 gg/ml for 30 min at 
37 ~ C) followed by hybridization with individual 
antisense riboprobes. In each case, control hybrid- 
izations resulted in complete loss of hybridization 
signal. Sections were viewed using darkfield mi- 
croscopy, and all images were acquired on a Nikon 
Microphot FXA microscope utilizing a Kodak DCS 
2000 digital camera and Adobe Photoshop 2.5.1 
software for Macintosh. 
Antibodies 
The B3A.1 rabbit polyclonal anti-neurofibromin 
antibody was prepared against a fusion protein con- 
taining the terminal 73 amino acids of the full length 
neurofibromin protein (excluding the 48a exon 
coding sequence) as previously described [15]. 
S-100-~ antibodies were purchased from Boehrin- 
get Mannheim and used according to the manufac- 
turers recommendations. 
Immunohistochemistry 
Paraffin-embedded sections were surrounded with 
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a Teflon coating using a Pap-pen (Kyota Co.), and 
incubated for one hour in a blocking solution con- 
sisting of Superblock buffer (Pierce) 0.3% Triton 
X-100 and 0.3% Tween-20, 1.0% porcine gelatin 
(Sigma) and 1.5 % normal goat serum (Vector). Pri- 
mary and secondary antibodies were diluted in the 
same solution diluted 1:1 with Superblock buffer. 
Primary incubations were placed at 4 ~ C overnight 
(12-16 hours). B3A.1 was used at a 1:300 dilution 
while the S-100 antibody was used at a 1:200 dilu- 
tion. Slides were then washed 3 x 5 minutes with 
phosphate-buffered saline, pH 7.2 (PBS) and 
placed in secondary antibody (anti-rabbit Cy3 con- 
jugated antibody; Jackson Immunochemicals), 
washed 3 x 5 minutes in PBS and coverslipped in 
PBS, for examination under fluorescence. 
Northern blot 
Total RNA was isolated from cells after rinsing the 
dishes in cold PBS using a modification of the acid- 
phenol method (RNAzol B; Tel-Test, Inc). RNA 
concentrations were calculated by UV absorption 
and stored at - 70 ~ C in DEPC-treated water. Sam- 
ples of total RNA (20 gg/lane) were separated on 
1.2% agarose-0.37 M formaldehyde gels for 3.5 
hours, stained briefly with ethidium bromide and 
photographed. RNA was transferred onto nitrocel- 
lulose membranes (Hybond, Amersham) and 
cross-linked by UV exposure [16]. The 1.2 kb EcoRI 
fragment of plasmid P5, 2.2 kb EcoR1 fragment 
containing full-length NF2 ([17]; kindly provided by 
Dr. J. Gusella, MGH), 1.0 kb Po cDNA fragment, 
and 1.0 kb [3-actin cDNA probe were labeled with 
32p-dCTP using random hexamers and purified by 
spin-column chromatography. Membranes were 
prehybridized in l x Denhardt's solution (1% 
SDS/0.2 M dextran sulfate/1 M NaC1) containing 
100 gg per ml salmon sperm DNA for 3-12 hours at 
65 ~ C, and then hybridized with the probe over- 
night at 65 ~ C. Hybridizations with the NF2 cDNA 
probe were performed at 42 ~ C overnight. Mem- 
branes were then washed in 2 x SSC, 0.1% SDS and 
exposed to film at - 70 ~ C for 2-5 days. 
106 
tively. S-100-~ primers amplify a 223 nucleotide 
product ( 5 ' - G G G A A T T C G G A T G T C T G A G C  
T G G A G A A G - 3 '  and 5 ' -GCGGATCCACTCCT 
GGAAGTCACACTCC-3 ' ) .  Cyclophilin primers 
amplify a 206 nucleotide product used as an internal 
control for the amount  of RNA in each sample (5'- 
A T G G T C A A C C C C A C C G T G T T - 3 '  and 5'-CG 
TTGTAAGTCACCACCCT-3 ' ) .  Twenty-five cy- 
cles were chosen based on previous experiments 
demonstrating a linear relationship between input 
DNA and obtained RT-PCR product with these 
conditions. RT-PCR products were separated on 
8% polyacrylamide gels along with ~;~-Hae III 
markers and visualized by staining with ethidium 
bromide. 
Fig. 1. Expression of NF1 RNA in tumor 021194 and cultured 
Schwann cells. Total RNA extracted from normal fibroblasts 
(lane A), normal Schwann cells (lane B), 021194 Schwann cells 
(lane C), and tumor 021194 (lane D) were analyzed by Northern 
blot analysis as described in the Materials and Methods section. 
The Hybond-N filter containing these RNAs was sequentially 
probed with the P5 NF1 cDNA probe, the complete NF2 cDNA 
probe (pBlueScript.JJR.1), a Po cDNA probe and the ~3-actin 
probe. Barely detectable levels of NF1 RNA could be seen in the 
021194 tumor whereas abundant NF1 RNA was found in the 
Schwann cells cultured from this tumor. Equivalent amounts of 
NF2 RNA were seen in the tumor relative to [3-actin expression. 
Normal cultured Schwann cells express equivalent amounts of 
NF1 mRNA as cultured fibroblasts (data not shown). 
Reverse-transcribed P C R  analysis 
RNA was extracted by conventional methods and 
three micrograms were reverse-transcribed as pre- 
viously described using SuperScript II (Bethesda 
Research Laboratories) and RNase inhibitors [7]. 
NF1 cDNA was amplified using primers (5'-ATT 
G T G A T C A C A T C C T C T G A T T G G - 3 '  and 5'-CA 
T G A T T G G C A A T A C T C T G A A - 3 ' )  which gener- 
ate both the type 1 and type 2 NF1 isoform products 
for 25 cycles with a 55 degree annealing step [18,19]. 
Type 1 NF1, lacking the 63 nucleotide exon 23a in- 
sertion, and type 2 NF1 containing this insertion, 
migrate as 376 and 439 nucleotide products, respec- 
Results 
Patient 021194 
C.S. is an eleven year old body first noted to have 
thoracic spinal schwannomas at age 6 when he pre- 
sented with back pain, lower extremity hyper-re- 
flexia and mild leg weakness. Surgical resection of 
this tumor confirmed the diagnosis of schwannoma. 
Over the next few years, he underwent two addi- 
tional surgical procedures for tumor debulking, 
most recently in February 1994 when he was seen in 
our Neurofibromatosis Program. At that time, he 
had four cafe-au-lait spots, no Lisch nodules, no 
family history of neurofibromatosis, a normal head 
MRI (no vestibular neuromas or meningiomas), 
normal stature and head circumference for his age 
(50th percentile) and no axillary or inguinal freck- 
ling. Mild scoliosis was noted on examination (ten 
degrees with a convexity to the right). He has con- 
tinued to do well after his surgeries with only mini- 
mal lower extremity weakness. 
Examination of the tumor resected in 1994 dem- 
onstrated eosinophilic spindle cells with prominent 
nucleolar palisading and Verocay body formation. 
The tumor consisted of densely cellular Antoni A 
tissue with relatively little Antoni B tissue. Immu- 
nohistochemical analysis with S-100 antibodies 
demonstrated intense labeling of the Schwann cells 
in the tumor. 
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Fig. 2. Expression of NF1 in tumor 021194. (A) NF1 expression by in situ hybridization and immunohistochemistry. Abundant expression 
of S-100 protein could be detected in the tumor (panel A) whereas no neurofibromin was found using the B3A.1 antibody (panel C). 
Preimmune control for the B3A.1 antibody (panel D) and secondary antibody alone control (panel B) demonstrated no staining of the 
tumor. Likewise, no NF1 RNA expression could be detected by in situ hybridization as described in the Material and Methods section. 
Panel E depicts hybridization with the sense NF1 cRNA probe while antisense NF1 cRNA probe hybridization is shown in panel E No 
differences between sense and antisense hybridization could be demonstrated. (B) Reverse-transcribed (RT) PCR analysis of tumor 
021194 and derivative Schwann cells and fibroblasts. Three micrograms of RNA was reverse-transcribed as described in the Materials and 
Methods section and used for PCR analysis of NF1, S-100 and cyclophilin RNA expression. The conditions and cycle number were chosen 
based on previous experiments demonstrating a semi-quantitative relationship between input cDNA and output PCR product. Whereas 
abundant amounts of cyclophilin and S-100 RNA could be detected in tumor 021194, little NF1 RNA could be detected (lane E). In 
contrast, NF1 RNA could be detected in normal Schwann cells (lane C) and fibroblasts (lane A) as well as the cultured Schwann cells (lane 
D) and fibroblasts (lane B) from this tumor. 
Lack o f  NF1 expression in Schwannoma 021194 
A representative Northern blot is shown in Fig. 1. 
As can be seen, there is abundant expression of 
NF2, myelin Po and actin m R N A  in the tumor (lane 
D) but markedly reduced expression of NF1. Abun- 
dant expression of NF1, NF2, actin and myelin Po 
R NA could be detected in Schwann cells derived 
from normal sciatic nerve (data not shown). Like- 
wise, no significant NF1 expression could be detect- 
ed by in situ hybridization using an antisense NF1 
cDNA riboprobe (Fig. 2A; panel E) when com- 
pared to the NF1 sense riboprobe control (Fig. 2A; 
panel F). This result was verified by immunohisto- 
chemistry using B3A.1 polyclonal neurofibromin 
antiserum (Fig. 2A; panel C). Positive antisense 
NF1 riboprobe and B3A.1 antibody staining were 
observed with other tumors and rat brain controls 
(data not shown). In contrast, the tumor expresses 
S-100 protein as detected using the S-100 antibody 
(Fig. 2A; panel A). Appropriate negative controls 
included preimmune B3A.1 antiserum (Fig. 2A; 
panel D) and secondary antibody alone (Fig. 2A; 
panel B). Lastly, the expression of NF1 m R N A  was 
nearly undetectable by RT-PCR analysis whereas 
S-100 and cyclophilin m R N A  could be easily dem- 
onstrated (Fig. 2B; lane E). These results collective- 
ly demonstrate that NF1 expression is greatly re- 
duced in this Schwann cell tumor. 
Cultured Schwann cells from tumor 021194 
demonstrate NF1 expression 
Schwann cells cultured from this tumor were found 
to express NF1 m R N A  by Northern blot and RT- 
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Fig. 3. Cultured Schwann cells from tumor 021194 and from normal human peripheral nerve. Cells seeded on glass coverslips were stained 
for S-100 protein by indirect immunofluorescence. Approximately 30% of the cells in primary dissociates of the tumor stained intensely 
with antibodies to S-100 (A). Morphologically, these cells differed distinctly from primary Schwann cells isolated from normal nerves 
which are typically bipolar (C). Early passage Schwann cells from the tumor resembled the enlarged cells with multiple processes which 
began to appear in long-term cultures of normal Schwann cells shown here at passage 12 (D). The number of multiprocess Schwann cells 
cultured from the tumor declined with successive passages. By passage five, more transformed-appearing cells expressing 10w levels of 
S-100 in the cytoplasm and nucleus predominated (B). Magnification is approximately 100 x. 
PCR analysis. High levels of N F I  expression can be 
seen in the cultured Schwann cells f rom this tumor  
by Nor thern  blot (Fig. 1; lane C) and RT-PCR (Fig. 
2B; lane D). Likewise, abundant  expression of 
S-100, NF2, actin and Po m R N A  could be demon-  
strated in these Schwann cells (Fig. 1; lane C and 
Fig.2B; lane D)  as compared  to Schwann cells ob- 
tained f rom normal  human sciatic nerve (Fig. 1; lane 
B and Fig. 2B; lane C). Immunocytochemist ry  using 
the B3A.1 polyclonal antibody also detected neuro- 
fibromin expression in these cultured cells (data not 
shown). These results demonstrate  that NF1 ex- 
pression may be upregulated in cultured Schwann 
cells taken f rom a Schwann cell tumor in which no 
NF1 expression could be detected. 
Tumor  021194 Schwann  cells maintain NF1 expres- 
sion in culture 
The expression of NF1 in Schwann cells taken f rom 
a tumor not expressing detectable levels of NF1 
m R N A  or protein may represent an artifact of in 
vitro manipulation. Two possibilities exist to ex- 
plain the above results: (1) normal  Schwann cells 
contaminating the tumor  were expanded in lieu of 
the schwannoma tumor Schwann cells and (2) 
growth factors added to the cultured cells induced 
the expression of NF1. To address these possibili- 
ties, additional analysis was per formed on these cul- 
tured Schwann cells. First, these tumor  Schwann 
cells were morphologically different than 'normal '  
Schwann cells (Fig. 3). Second, these Schwann cells 
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retained their ability to express NF1 mRNA even 
after three months in culture as demonstrated by 
RT-PCR (data not shown). Lastly, removal of all ex- 
ogenously added growth factors from the medium 
had no effect on NF1 expression, in that Schwann 
cells grown in the presence or absence of these fac- 
tors express similar amounts of NF1 mRNA by RT- 
PCR (Fig. 4). 
Discussion 
NF1 and NF2 are distinct clinical entities which 
have in common tumors of Schwann cell origin. Pa- 
tients with NF1 present with cafe-au-lait spots, 
freckling in non-sun-exposed areas, Lisch nodules 
(iris hamartomas) and neurofibromas (benign tu- 
mors composed predominantly of Schwann cells) 
[20]. NF2, on the other hand, more commonly pre- 
sents with bilateral vestibular neuromas and menin- 
giomas without Lisch nodules, freckling or cafe-au- 
lait spots [21]. In both disorders, there is an in- 
creased incidence of malignancy, owing to the fact 
that both genes are tumor suppressor genes. 
Examination of NF1 expression in NFl-related 
Schwann cell tumors has demonstrated loss of neu- 
rofibromin expression in malignant neurofibrosar- 
coma cell lines [8, 9]. Introduction of a portion of 
NF1 into these malignant Schwann cells resulted in 
decreased cell proliferation, suggesting that the 
lack of neurofibromin downregulation of p21-ras 
activity is associated with tumor cell proliferation. 
However, less is known about the expression of NF1 
in the benign neurofibroma. Recent evidence from 
our laboratory suggests that NF1 expression is re- 
duced in the Schwann cells, but not in the fibro- 
blasts, cultured from NF1 neurofibromas (JLR and 
DHG, manuscript in preparation). Studies examin- 
ing the expression of NF2 in Schwann cell tumors 
have demonstrated mutations in over fifty percent 
of NF2-related as well as sporadic vestibular neuro- 
mas [22, 23]. Other studies have shown frequent de- 
letions and loss of heterozygosity in the region of 
NF2 in both sporadic and NF2-related vestibular 
neuromas [24, 25]. 
The results described in this manuscript demon- 
strate reduced expression of NF1 mRNA and pro- 
Fig. 4. NFI RNA expression is detected in cultured tumor 
Schwann cells growth in the presence or absence of  growth factors. 
Three micrograms of RNA was reverse-transcribed as described 
in the Materials and Methods section and used for PCR analysis 
of NF1 and cyclophitin RNA expression. The conditions and cy- 
cle number were chosen based on previous experiments demon- 
strating a semi-quantitative relationship between input cDNA 
and output PCR product. There is continued expression of NF1 
RNA in these cultured cells grown in the presence (lane B) or 
absence (lane C) of growth factors (recombinant glial growth 
factor and forskolin) compared to the original batch of 021194 
tumor Schwann cells taken after three weeks in vitro (lane A). 
tein in a Schwann cell tumor from a patient without 
NF1 or NF2. This finding is not surprising given the 
possible function(s) of neurofibromin in Schwann 
cell differentiation. The unexpected result of 'nor- 
mal' NF1 expression in the cultured Schwann cells 
from this tumor suggest a novel mechanism for 
growth regulation in tumors. The lack of NF1 ex- 
pression in the tumor is unlikely to be artifactual 
since normal expression of other mRNAs (S-100, 
NF2, Po and actin) could be demonstrated using a 
variety of different molecular biology techniques 
including Northern blot, RT-PCR, in situ hybridiza- 
tion and immunohistochemistry. Similarly, the ex- 
pression of NF1 mRNA and protein in the cultured 
Schwann cells is unlikely to be artifactual. Two ma- 
jor possibilities can be invoked to explain this in- 
creased expression: (1) The increased expression is 
related to the culture conditions. To this end, we have 
demonstrated that the expression of NF1 mRNA is 
not dependent on exogenously added growth fac- 
tors, as removal of these factors does not result in 
decreased NF1 expression. Likewise, there is no 
change in NF1 expression in these cells over time in 
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culture and the 021194 tumor cells still express NF1 
m R N A  after 3 months in culture. Even if the act of 
plating these cells in vitro resulted in increased NF1 
expression, this would suggest that at least one 
functional NF1 allele exists in these tumor cells 
which is responsive to upregulation. (2) The in- 
creased expression o f  NF1 m R N A  is related to the 
selective expansion of contaminating 'normal '  
Schwann cells. This is an unlikely possibility since 
the morphological and growth characteristics of 
these Schwann cells do not resemble those seen in 
cultured Schwann cells from normal sciatic nerve. 
In addition, there is no growth advantage for nor- 
mal Schwann cells that would contribute to their 
preferential expansion. On the contrary, the 'tu- 
mor '  Schwann cells would be expected to be prefer- 
entially expanded since their growth potential is 
augmented by definition during the process of ma- 
lignant transformation. Studies are underway to de- 
termine whether NF1 expression can be downreg- 
ulated by implanting the 021194 Schwann cells into 
mice. 
Examination of other Schwann cell tumors in our 
laboratory has failed to detect further examples of 
reversible NF1 downregulation. Although this is 
not the common mechanism for reducing TSG ex- 
pression in tumors, it represents an important ob- 
servation in that it offers exciting possibilities for 
the potential treatment of selected tumors through 
modulation of NF1 expression. Future studies di- 
rected at defining the mechanism(s) underlying 
transcriptional regulation of NF1 expression in nor- 
mal and tumor cells may provide potential ther- 
apies for the pharmacologic treatment of these tu- 
mors. 
Acknowledgements 
We wish to thank the members of William D. Snid- 
er's laboratory, particularly Derek Molliver and Dr. 
Douglas Wright, for their help with immunohisto- 
chemistry and in situ hybridization and Dr. James E 
Gusella for the pBlueScript.JJR1 (NF2) cDNA. We 
likewise appreciate the invaluable discussions pro- 
vided by Drs. S. Bruce Dowton, Karen K. Norton, 
Kevin Roth, Robert  Schmidt and Eugene M. John- 
son, Jr. D H G  is the recipient of a Clinical Investiga- 
tor Award from the NINDS (NS-01590-04) as well 
as generous support from Schnuck Markets, Inc. 
IS-S is the recipient of a McDonnell Center for 
Molecular Neuroscience Research Fellowship. JLR 
is supported by grants from the University of Michi- 
gan Cancer Center and the National Neurofibro- 
matosis Foundation. 
References 
1. Weinberg RA: Tumor suppressor genes. Science 254: 1138- 
1146,1991 
2. Seizinger B R: NFh a prevalent cause of tumorigenesis in hu- 
man cancers? Nature Genetics 3: 97-99, 1993 
3. Riccardi VM: Neurofibromatosis: Past, present and future. 
New England J Medicine 324: 1283-1285, 1991 
4. Bader JL: Neurofibromatosis and cancer. Annals NY Acad- 
emy of Science 486: 57-65, 1986 
5. Dastou MM, Scrable H, Norlund M, Sturbaum AK, Nissen 
LM, Ratner N: The protein product of the neurofibromato- 
sis type 1 gene is expressed at highest abundance in neurons, 
Schwann cells and oligodendrocytes. Neuron 8: 415428, 
1992 
6. Gutmann DH, Collins FS: The neurofibromatosis type 1 
gene and its protein product, neurofibromin. Neuron t0: 
335-343, 1993 
7. Gutmann DH, Tennekoon GI, Cole JL, Collins FS, Rutkow- 
ski JL: Modulation of the neurofibromatosis type 1 gene 
product, neurofibromin, during Schwann cell differentia- 
tion. J Neuroscience Res 36: 216--223, 1993 
8. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins 
FS, Downward J: Aberrant regulation of ras proteins in tu- 
mour cells from type 1 neurofibromatosis patients. Nature 
356: 713-715, 1992 
9. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner 
N, Vass WC, Lowy DR: Abnormal regulation of mammalian 
p21 ras contributed to malignant tumor growth in von Reck- 
linghausen (type 1) neurofibromatosis. Cell 69: 265-273, 
1992 
10. Rutkowski JL, Tennekoon GI, McGillicuddy J: Selective 
culture of mitotically active human 8chwann cells from 
adult sural nerves. Ann Neurology 31: 580-586, 1992 
11. Singer KH, Scearce RM, Tuck DT et al.: Removal of fibro- 
blasts from human epithelial cell cultures with use of a com- 
plement fixing monoclonal antibody reactive with human fi- 
broblasts and monocytes/macrophages. J Invest Dermat 92: 
166-170,1989 
12. Marchionni MA, Goodearl ADJ, Chen MS et al.: Glial 
growth factors are alternatively spliced erbB2 ligands ex- 
pressed in the nervous system. Nature 362: 312-318,1993 
13. Marchuk DA, Saulino AM, Tavakkol R, Swaroop M et al.: 
cDNA cloning of the type 1 neurofibromatosis gene: Corn- 
plete sequence of the NF1 product. Genomics 11: 931-940, 
1991 
14. Mu X, Silos-Santiago I, Carroll SL, Snider WD: Neurotro- 
phin receptor genes are expressed in distinct patterns in the 
developing dorsal root ganglia. J Neuroscience 13: 4029- 
4041,1993 
15. Gutmann DH, Wood DL, Collins FS: Identification of the 
neurofibromatosis type 1 gene product. Proc Natl Acad Sci 
USA 88: 9658-9662, 1991 
16. Wallace MR, Marchuk DA, Andersen LB et al.: Type 1 neu- 
rofibromatosis gene: Identification of a large transcript dis- 
rupted in three NF1 patients. Science 249: 181-186, 1990 
17. Trofatter JA, MacCollin MM, Rutter JL et al.: A novel moe- 
sin-, ezrin-, radixin-like gene is a candidate for the neuro- 
fibromatosis 2 tumor suppressor. Cell 72: 1-20, 1993 
18. Andersen LB, B allester R, Marchuk DA et al.: A conserved 
alternative splice in the von Recklinghausen neurofibroma- 
tosis (NF1) gene produces two neurofibromin isoforms, 
both of which have GTPase activating protein activity. Mol 
Cell Bio113: 487-495, 1993 
19. Nishi T, Lee PSY, Oka K, Levin VA, Tanase S, Morino Y, 
Saya H: Differential expression of two types of the neuro- 
fibromatosis type 1 (NF1) gene transcripts related to neuro- 
nal differentiation. Oncogene 6: 1555-1559, 1991 
20. Riccardi VM, Eichner JE: Neurofibromatosis: Phenotype, 
111 
Natural History and Pathogenesis. Johns Hopkins Universi- 
ty Press Baltimore, MD 2nd edition, 1992 
21. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, New- 
ton V, Harris R: A clinical study of type 2 neurofibromatosis. 
Quarterly Journal of Medicine 304: 603-618, 1992 
22. Wolff RK, Frazer KA, Jackler RK, Lanser MJ, Pitts LH, Cox 
DR: Analysis of chromosome 22 deletions in neurofibroma- 
tosis type 2-related tumors. Am J Human Genetics 51: 478- 
485, 1992 
23. Bourn D, Carter SA, Mason S, Evans GDR, Strachan T: 
Germline mutations in the neurofibromatosis type 2 tumour 
suppressor gene. Human Molecular Genetics 3: 813-816, 
1994 
24. Rutt ledge MH, Sarrazin J, Rangaratnam S, Phelan CM et aL : 
Evidence for the complete inactivation of the NF2 in the ma- 
jority of sporadic meningiomas. Nature Genetics 6:180-184, 
1994 
25. Bianchi AB, Hara T, Ramesh V, Gao J et aL: Mutations in 
transcript isoforms of the neurofibromatosis 2 gene in mul- 
tiple human tumour types. Nature Genetics 6:185-192,1994 
Address for  offprints: D.H. Gutmann, Department of Neurology, 
Washington University School of Medicine, Box 8111, 660 S. Eu- 
clid Avenue, St. Louis, MO 63110, USA 
